Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for…
<!-- Name:DistributionId Value:8795546 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Cyclerion Therapeutics
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular…
CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for ongoing CY6463 clinical studies in…
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS…
Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity…
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022…
Characterizing the novel neuropharmacology of CY6463’s NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich,…
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore…
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in…
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore…